cbdMD, Inc. (YCBD) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.78. It has a SharesGrow Score of 44/100, indicating a mixed investment profile with 1 out of 7 criteria passed.
Valuation: YCBD trades at a trailing Price-to-Earnings (P/E) of -2.6 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.05.
Financials: revenue is $19M, -17.5%/yr average growth. Net income is $2M (loss), growing at +65.9%/yr. Net profit margin is -10.6% (negative). Gross margin is 56.5% (-6.6 pp trend).
Balance sheet: total debt is $778M against $7M equity (Debt-to-Equity (D/E) ratio 107.7, leveraged). Current ratio is 2.05 (strong liquidity). Debt-to-assets is 7468.7%. Total assets: $10M.
Analyst outlook: 2 / 3 analysts rate YCBD as buy (67%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 35/100 (Fail), Future 55/100 (Partial), Income 10/100 (Fail).
